Liver Disease Diagnostics Market To Reach $66.4 Billion by 2033

Liver Disease Diagnostics Market Growth & Trends

The global liver disease diagnostics market size is expected to reach USD 66.4 billion by 2033, registering a CAGR of 6.3% from 2026 to 2033, according to a new report by Grand View Research, Inc. increasing funding and research initiatives undertaken by market players is one of the major factors expected to propel market growth. For instance, in November 2019, Glycotest, Inc. received the second USD 3.0 million tranche of USD 10.0 million Series A funding from Shanghai Fosun Pharmaceutical Co., Ltd.(Fosun Pharma). Under this investment, Glycotest, Inc. transferred HCC panel technology to Fosun Pharma to commercialize in China and develop tests for liver cancer and liver fibrosis that are currently under pipeline.

Companies are focusing on collaborations and partnership to improve the quality of care,which is anticipated to drive the market. For instance, in October 2019, Perspectum Diagnostics entered into a partnership to offer LiverMultiScan at Precious Medical Center in Singapore. The aim of this partnership was to create awareness among people to consider liver checking as an integral part of their health screening.

Researchers conducting studies to support the development of novel diagnostic methods that can accurately differentiate between benign and malignant lesions are expected to fuel market growth. For instance, researchers from Charité - Universitätsmedizin Berlin used tomoelastography to visualize mechanical properties of tumors and developed a new Magnetic Resonance Imaging (MRI) technique to detect grading of tumor consistency.

Furthermore, companies are conducting clinical trials to develop new tests with high sensitivity and specificity. For instance, Laboratory for Advanced Medicine is conducting a clinical trial on 1,600 patients with liver cirrhosis using invasive biopsy through quantification of cfDNA methylation and comparing it with ultrasound technique. The test is projected to be completed in 2020.

Development and commercialization of accurate diagnostic methods is expected to boost the market. For instance, in March 2020, ENDRA Life Sciences Inc. received CE mark for TAEUS FLIP system. This system measures liver fat to identify and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). It is an ultrasound system that accurately and at point of care quantifies fat in the liver.

 Request a free sample copy or view report summary: Liver Disease Diagnostics Market Report

Liver Disease Diagnostics Market Report Highlights

• Based on diagnosis technique, the NAFLD segment dominated the market with a 26.1% revenue share in 2025, driven by rising obesity, type 2 diabetes, dyslipidemia, and metabolic syndrome worldwide.

• Based on disease, the ion-exchange chromatography segment dominated the global Liver Disease Diagnostics market, accounting for 33.6% of revenue in 2025, owing to its high analytical accuracy, excellent separation of hemoglobin fractions, effective detection of hemoglobin variants, and compatibility with automated high-throughput laboratory workflows.  

• Based on end use, the hospitals segment accounted for the largest revenue share of 44.8% in 2025 due to the availability of advanced diagnostic infrastructure, multidisciplinary clinical expertise, and integrated care pathways for the diagnosis, staging, and monitoring of acute and chronic liver diseases.

• North America liver disease diagnostics market dominated the global industry and accounted for a 43.1% share in 2025. The region leads due to its advanced healthcare infrastructure, widespread adoption of non-invasive diagnostic technologies, strong reimbursement framework, and high prevalence of MASLD, chronic viral hepatitis, cirrhosis, and hepatocellular carcinoma. 

Liver Disease Diagnostics Market Segmentation

Grand View Research has segmented the global liver disease diagnostics market based on diagnosis technique, disease, end-use, and region:

Liver Disease Diagnostics Diagnosis Technique Outlook (Revenue, USD Billion, 2021 - 2033)

• Laboratory Tests

• Imaging

• Endoscopy

• Biopsy

• Others

Liver Disease Diagnostics Disease Outlook (Revenue, USD Billion, 2021 - 2033)

• NAFLD

• NASH

• Fibrosis

• Cirrhosis

• HCC

• Others

Liver Disease Diagnostics End Use Outlook (Revenue, USD Billion, 2021 - 2033)

• Hospitals

• Laboratories

• Others

Liver Disease Diagnostics Regional Outlook (Revenue, USD Billion, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Norway

  • Denmark

  • Sweden

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List Of Key Players Liver Disease Diagnostics Market

• Abbott

• F. Hoffmann-La Roche Ltd.

• Thermo Fisher Scientific Inc.

• Randox Laboratories Ltd.

• Boston Scientific Corporation

• Laboratory Corporation of America Holdings

• Fujifilm Corporation

• Horiba Medical

• Siemens Healthcare GmbH

• Quest Diagnostics